The Health Pod

The COVID-19 crisis has required competition authorities to adjust their enforcement priorities and seen a temporary relaxation of certain competition laws in response to the pandemic. In this episode of The Health Pod, Irena Apostopoulos joins Dave Wardell to discuss the impact of the pandemic on competition law enforcement in the UK and EU in the healthcare and life sciences industry, as well as heightened compliance risks and the risk of dawn raids. As competition authorities begin to prepare once again to conduct dawn raids as lockdown measures slowly ease, dawn raid preparation will look very different in a post-COVID-19 world and this episode highlights some of the key measures that companies should put in place now to ensure that they are prepared, even with employees continuing to work remotely.

The lengthy, expensive and complex nature of drug development has brought about the emergence of alternative funding entities to help boost R&D productivity, lower costs and mitigate risks. In this episode, Randall Sunberg joins David Wardell in discussing how these investment companies are bridging the funding gap, and the types of agreements and due diligence involved in these arrangements.

The disruptive impact of COVID-19 has forced the healthcare and life sciences industries to adapt in different ways. In this episode of The Health Pod, Els Janssens and Christian Lopez-Silva, join Dave Wardell in discussing the effect COVID-19 has had on the management of clinical trials in the EU and Mexico and how the regulators have dealt with these impacts.

Resolving the health crisis demands an immediate response from regulatory agencies. In this episode, Kamleh Nicola and Veleka Peeples-Dyer join Dave Wardell in discussing some of the most significant responses by Health Canada and the FDA to COVID-19.